Skip to:
-

Prof Andreas Strasser

Division Head
View profile on Find a Researcher
Areas
Diseases
Technologies
Themes / Divisions
Sections on this page

About

My research is focused on understanding the molecular mechanisms of apoptosis, with a particular focus on leukaemias and lymphomas. To do this, we use gene-targeting technologies as well as biochemical and molecular biology tools.

This is answering important questions about:

– The regulation of apoptosis and other forms of cell death
– How apoptosis and other forms of cell death are disrupted during development of haematopoietic and epithelial tumours, and autoimmune disease
– The contribution of impaired apoptosis and possibly other forms of cell death to chemoresistance
– How we can manipulate apoptosis and possibly other forms of cell death for therapeutic benefit
– How the tumour suppressor p53 prevents tumour development and how it functions in cancer therapy
– Our long-term ambition is to use this knowledge to develop new approaches to the treatment and prevention of cancer and autoimmune disease.

My group has been set up to encompass a very broad technology base, bringing together expertise in:

– In vivo biology
– Transgenic and gene targeting technology
– Molecular biology, including lentiviral and shRNA vector production as well as CRISPR mediated genome editing in cell lines, primary cells and in mice
– Biochemistry
– Yeast genetics
– Monoclonal antibody production
– Immunology and haematology

This allows us to tackle many important questions in cell death, molecular oncology and immunology and helped to establish our group at the forefront in our area of research.

Publications

Selected publications from Prof Andreas Strasser

Cummings MC, Vaux DL, Strasser A, Kluck R. John F. R. Kerr (1934–2024). Cell Death & Differentiation. 2024;:10.1038/s41418-024-01338-x

Shi Y, Strasser A, Green DR, Latz E, Mantovani A, Melino G. Legacy of the discovery of the T-cell receptor: 40 years of shaping basic immunology and translational work to develop novel therapies. Cellular & Molecular Immunology. 2024;21(7):10.1038/s41423-024-01168-4

Audiger C, Laâbi Y, Nie J, Gibson L, Wilson-Annan J, Brook-Carter P, Kueh A, Harris AW, Naik S, Nutt SL, Strasser A, Adams JM, Bouillet P, Chopin M. Mis-expression of GATA6 re-programs cell fate during early hematopoiesis. Cell Reports. 2024;43(5):10.1016/j.celrep.2024.114159

Diepstraten ST, Yuan Y, La Marca JE, Young S, Chang C, Whelan L, Ross AM, Fischer KC, Pomilio G, Morris R, Georgiou A, Litalien V, Brown FC, Roberts AW, Strasser A, Wei AH, Kelly GL. Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers. Cancer Cell. 2024;42(5):10.1016/j.ccell.2024.04.004

Chen T, Lieschke E, Scott L, Boyd D, Sutherland K, Strasser A, Kelly G. Abstract LT06: Understanding the Role of Mutant TP53 in Lung Cancer Using Novel Genetically Engineered Mouse Models. Cancer Research. 2024;84(8_Supplement):10.1158/1538-7445.fcs2023-lt06

Wang Z, Burigotto M, Ghetti S, Vaillant F, Tan T, Capaldo BD, Palmieri M, Hirokawa Y, Tai L, Simpson DS, Chang C, Huang AS, Lieschke E, Diepstraten ST, Kaloni D, Riffkin C, Huang DCS, Suen CSNLW, Garnham AL, Gibbs P, Visvader JE, Sieber OM, Herold MJ, Fava LL, Kelly GL, Strasser A. Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells. Cancer Discovery. 2024;14(2):10.1158/2159-8290.cd-23-0402

La Marca JE, Aubrey BJ, Yang B, Chang C, Wang Z, Kueh A, Tai L, Wilcox S, Milla L, Heinzel S, Vremec D, Whelan L, König C, Kaloni D, Voss AK, Strasser A, Diepstraten ST, Herold MJ, Kelly GL. Genome-wide CRISPR screening identifies a role for ARRDC3 in TRP53-mediated responses. Cell Death & Differentiation. 2024;31(2):10.1038/s41418-023-01249-3

Brennan MS, Brinkmann K, Romero Sola G, Healey G, Gibson L, Gangoda L, Potts MA, Lieschke E, Wilcox S, Strasser A, Herold MJ, Janic A. Combined absence of TRP53 target genes ZMAT3, PUMA and p21 cause a high incidence of cancer in mice. Cell Death & Differentiation. 2024;31(2):10.1038/s41418-023-01250-w

Newton K, Strasser A, Kayagaki N, Dixit VM. Cell death. Cell. 2024;187(2):10.1016/j.cell.2023.11.044

Yuan Y, Diepstraten ST, Brown FC, Litalien V, Strasser A, Kelly GL, Roberts AW, Wei AH. Direct, Potent, and TP53-Independent Activity of Sting Agonists Against Acute Myeloid Leukaemia Enhances Venetoclax Efficacy In Vivo. Blood. 2023;142(Supplement 1):10.1182/blood-2023-179698

Lab research projects

Interested in supporting our research?

Your support will help WEHI’s researchers make discoveries and find treatments to ensure healthier, longer lives for you and your loved ones.

Contact our friendly team to find out how you can help.

(03) 9345 2403
fundraising@wehi.edu.au

Donate now
© WEHI 2024
Close